My response to the January 27th New York Times article Venture Capital Blogs? They’re About Anything But, by Matt Richtel. Disclaimer: I am not nor do I pretend to be a VC and cannot accept any responsibility or liability for the improper operation of the site, article or reliance by any person on this site [...]

• 53View 2 Comments...http://clsdf.com/2006/01/in-defense-of-the-vc-blog/In+Defense+of+the+VC+Blog2006-01-30+18%3A10%3A00admin

And now for a shameless plug… I would like to quickly highlight for those nascent Colorado life science companies the Fitzsimons BioBusiness Incubator (FBBi). FBBi connects ideas, technologies and people to deliver targeted assistance to start-up companies and entrepreneurs. FBBi works tirelessly to unite industry experts, venture capitalists, private investors, and the researchers that move [...]

• 52http://clsdf.com/2006/01/the-business-of-science/The+Business+of+Science2006-01-29+07%3A35%3A00admin

It was an impressive 2005 for companies raising venture capital in Colorado. In 2004 total dollars raised was $386.3 million, while 2005 saw a dramatic increase by some 40%, totaling $647.2 million raised (data from Ernst & Young LLP and VentureOne Quarterly Venture Capital Report). Colorado surpassed the U.S. trend numbers; where $22.13 billion in [...]

• 51http://clsdf.com/2006/01/colorado-increases-vc-dollars-in-2005/Colorado+Increases+VC+Dollars+in+20052006-01-28+23%3A07%3A00admin

Replidyne, Inc., a biopharmaceutical company focused on the discovery and development of new anti-infective drugs, kicked off 2006 with a bang and has submitted a New Drug Application to the FDA for Orapem™ for the treatment of acute bacterial sinusitis, community acquired pneumonia, acute exacerbations of chronic bronchitis and uncomplicated skin and skin structure infections. [...]

• 50http://clsdf.com/2006/01/replidyne-files-nda-to-fda-for-orapem%e2%84%a2/Replidyne+Files+NDA+to+FDA+for+Orapem%E2%84%A22006-01-25+19%3A19%3A00admin

In a nutshell new guidance for Investigational New Drug applications will give the slow and methodical drug development process a much needed shot in the arm, favoring early stage life science companies and academia. The FDA has released new guidelines designed to allow entrance into human Phase 0/I clinical trails with human microdosing based upon [...]

• 49http://clsdf.com/2006/01/phase-0-a-new-era-in-drug-development/Phase+0%3A+A+New+Era+in+Drug+Development2006-01-24+16%3A27%3A00admin

Sirna Therapeutics, Inc. (Nasdaq: RNAI), announced today that the U.S. Patent and Trademark Office has granted Patent No. 6,989,442 for the chemical synthesis and manufacturing of ribonucleic acids. The patent broadly covers a process for the synthesis, deprotection and purification of nucleic acids with one or more ribonucleotides. This process is critical for the efficient [...]

• 48View 2 Comments...http://clsdf.com/2006/01/sirna-granted-patent-for-rnai-production/Sirna+Granted+Patent+for+RNAi+Production2006-01-24+14%3A36%3A00admin

CardioOptics, Inc., a medical device company developing and commercializing unique therapeutic catheter systems that allow doctors to see directly through flowing blood and inside the heart as they treat cardiovascular disease, has completed a $26.5 million Series B financing. The round was led by new investor Novo A/S and joined by Investor Growth Capital, Inc., [...]

• 47http://clsdf.com/2006/01/cardiooptics-completes-26-5m-series-b/CardioOptics+Completes+%2426.5M+Series+B2006-01-20+14%3A31%3A00admin

Allos Therapeutics, Inc. (Nasdaq: ALTH) announced the results from its Phase III study of Efaproxyn™ in patients with brain metastases. Results of the study, which were reported in the Journal of Clinical Oncology, suggest that the addition of Efaproxyn™ to whole brain radiation therapy may improve survival and response rates in patients with brain metastases, [...]

• 46View 2 Comments...http://clsdf.com/2006/01/allos-announces-survival-benefits-of-efaproxyn%e2%84%a2-in-phase-iii-study/Allos+Announces+Survival+Benefits+of+Efaproxyn%E2%84%A2+in+Phase+III+Study2006-01-09+21%3A14%3A00admin

Sirna Therapeutics, Inc. (Nasdaq: RNAI), is scheduled to present at the 24th Annual JPMorgan Healthcare Conference on Wednesday, January 11, 2006 at 4:00 p.m. PST. A live audio webcast of the presentation will be available at the Company’s web site at www.sirna.com. Sirna is a clinical-stage biotechnology company developing RNAi-based therapies for serious diseases and [...]

• 45View 1 Comment...http://clsdf.com/2006/01/sirna-to-webcast-jp-morgan-presentation/Sirna+to+Webcast+JP+Morgan+Presentation2006-01-09+21%3A04%3A00admin